Leukemia Research
Volume 27, Issue 5 , Pages 465-466 , May 2003

Waldenstrom’s macroglobulinemia: is there a place and time for a cease-fire?

Received 24 September 2002

References 

  1. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, et al.  Waldenstrom’s macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br. J. Haematol. 2000;108(4):737–742
  2. Zinzani PL, Gherlinzoni F, Bendandi M, Zaccaria A, Aitini E, Salvucci M, et al.  Fludarabine treatment in resistant Waldenstrom’s macroglobulinemia. Eur. J. Haematol. 1995;54(2):120–123
  3. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldentrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann. Oncol. 1995;6(1):49–52
  4. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom’s macroglobulinemia: clinical features, complications and management. J. Clin. Oncol. 2000;18(1):214–226
  5. Dimopoulos MA, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C, et al.  Treatment of Waldenstrom’s macroglobulinemia with thalidomide. J. Clin. Oncol. 2001;19(16):3593–3595
  6. Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, et al.  Rituximab therapy in Waldenstrom’s macroglobulinemia: preliminary evidence of clinical activity. Ann. Oncol. 1999;10(12):1525–1527

PII: S0145-2126(02)00225-4

doi: 10.1016/S0145-2126(02)00225-4

Leukemia Research
Volume 27, Issue 5 , Pages 465-466 , May 2003

Article Tools

* Image Usage & Resolution